Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
434.36 K
Value Traded
-
Short % Float
-
+6.74%Week
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
815.08 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
50.94 M
Float Shares
-
Insiders
-
Institutions
96.33%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
BBTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Bambusa Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bambusa Therapeutics, Inc.
3Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 3
Past FDA Catalysts and PDUFA Decisions
How BBTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every BBTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Jeggle Helmut WolfgangDirector, 10% Owner | BuyOffering | 375,000 9,264,301 held | $16.00 | 11/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BBTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BBTX for Q2 2026. | ||||
Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BBTX ranks across every disease it competes in
Competitive Position is a premium feature
See how BBTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBBTX News
-BBTX
Oct 30, 2026Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering
Bambusa Therapeutics priced its initial public offering of 10,555,555 shares at $16.00 per share. The company expects gross proceeds of $168,888,880 before expenses. Trading on the Nasdaq Global Select Market begins on October 30, 2026. The offering is scheduled to close on November 2, 2026, subject to customary conditions.
Read more →-BBTX
Oct 19, 2026Bambusa Therapeutics Presents Detailed BBT001 Atopic Dermatitis Proof-of-Concept Results at ISAD 2026
Bambusa Therapeutics presented detailed proof-of-concept results for BBT001 in moderate-to-severe atopic dermatitis at ISAD 2026. The findings highlighted rapid clinical activity and pharmacokinetic evidence. The company is advancing to a subcutaneous evaluation and preparing for a Phase 2b study to further assess BBT001's efficacy and safety.
Read more →-BBTX
Oct 1, 2026Bambusa Therapeutics Initiates Subcutaneous Dosing of BBT001 in Atopic Dermatitis, Following Compelling Intravenous Proof-of-Concept Data
Bambusa Therapeutics has initiated subcutaneous dosing of BBT001 in a Phase 1 trial for atopic dermatitis. This follows promising intravenous proof-of-concept results, showing significant clinical activity. The subcutaneous formulation aims to provide a more convenient treatment option with potential for less frequent dosing. The trial is currently enrolling patients across multiple regions.
Read more →About Bambusa Therapeutics, Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next BBTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime